165 related articles for article (PubMed ID: 17140722)
21. How are hemoglobin levels affected by androgen deprivation in non-metastatic prostate cancer patients?
Choo R; Chander S; Danjoux C; Morton G; Pearce A; Deboer G; Szumacher E; Loblaw A; Cheung P; Woo T
Can J Urol; 2005 Feb; 12(1):2547-52. PubMed ID: 15777493
[TBL] [Abstract][Full Text] [Related]
22. Quality of life after brachytherapy or radical prostatectomy for localized prostate cancer: a prospective longitudinal study.
Namiki S; Satoh T; Baba S; Ishiyama H; Hayakawa K; Saito S; Arai Y
Urology; 2006 Dec; 68(6):1230-6. PubMed ID: 17141839
[TBL] [Abstract][Full Text] [Related]
23. Time, symptom burden, androgen deprivation, and self-assessed quality of life after radical prostatectomy or watchful waiting: the Randomized Scandinavian Prostate Cancer Group Study Number 4 (SPCG-4) clinical trial.
Johansson E; Bill-Axelson A; Holmberg L; Onelöv E; Johansson JE; Steineck G;
Eur Urol; 2009 Feb; 55(2):422-30. PubMed ID: 18783877
[TBL] [Abstract][Full Text] [Related]
24. Efficacy of salvage radiotherapy plus 2-year androgen suppression for postradical prostatectomy patients with PSA relapse.
Choo R; Danjoux C; Gardner S; Morton G; Szumacher E; Loblaw DA; Cheung P; Pearse M
Int J Radiat Oncol Biol Phys; 2009 Nov; 75(4):983-9. PubMed ID: 19409726
[TBL] [Abstract][Full Text] [Related]
25. Quality of life in patients with skeletal metastases of prostate cancer and status prior to start of endocrine therapy: results from the Scandinavian Prostate Cancer Group Study 5.
Jønler M; Nielsen OS; Groenvold M; Hedlund PO; Damber L; Hedelin H; Waldén M;
Scand J Urol Nephrol; 2005; 39(1):42-8. PubMed ID: 15764270
[TBL] [Abstract][Full Text] [Related]
26. Health-related quality of life after adjuvant and salvage postoperative radiotherapy for prostate cancer - a prospective analysis.
Pinkawa M; Fischedick K; Asadpour B; Gagel B; Piroth MD; Holy R; Krenkel B; Eble MJ
Radiother Oncol; 2008 Jul; 88(1):135-9. PubMed ID: 18022263
[TBL] [Abstract][Full Text] [Related]
27. Recall of pretreatment symptoms among men treated with radiotherapy for prostate cancer.
Fransson P
Acta Oncol; 2005; 44(4):355-61. PubMed ID: 16120544
[TBL] [Abstract][Full Text] [Related]
28. Analysis of gastrointestinal and genitourinary morbidity of postoperative radiotherapy for pathologic T3 disease or positive surgical margins after radical prostatectomy using national cancer institute expanded common toxicity criteria.
Choo R; Pearse M; Danjoux C; Gardner S; Morton G; Szumacher E; Loblaw DA; Cheung P
Int J Radiat Oncol Biol Phys; 2008 Nov; 72(4):989-95. PubMed ID: 18436391
[TBL] [Abstract][Full Text] [Related]
29. Health-related quality of life 3 years after high-dose intensity-modulated radiotherapy with gold fiducial marker-based position verification.
Lips IM; van Gils CH; van der Heide UA; Kruger AE; van Vulpen M
BJU Int; 2009 Mar; 103(6):762-7. PubMed ID: 18990145
[TBL] [Abstract][Full Text] [Related]
30. Prospective study of quality of life of patients receiving treatment for prostate cancer.
Eller LS; Lev EL; Gejerman G; Colella J; Esposito M; Lanteri V; Scheuch J; Munver R; Lane P; Junchaya C; Alves L; Galli B; Watson R; Sawczuk I
Nurs Res; 2006; 55(2 Suppl):S28-36. PubMed ID: 16601630
[TBL] [Abstract][Full Text] [Related]
31. Short-, intermediate-, and long-term quality of life after laparoscopic radical prostatectomy--does the learning curve of LRP have a negative impact on patients' quality of life?
Wyler SF; Ruszat R; Straumann U; Forster TH; Provenzano M; Sulser T; Gasser TC; Bachmann A
Eur Urol; 2007 Apr; 51(4):1004-12; discussion 1012-4. PubMed ID: 17098352
[TBL] [Abstract][Full Text] [Related]
32. Testosterone recovery after prolonged androgen suppression in patients with prostate cancer.
Yoon FH; Gardner SL; Danjoux C; Morton G; Cheung P; Choo R
J Urol; 2008 Oct; 180(4):1438-43; discussion 1443-4. PubMed ID: 18710743
[TBL] [Abstract][Full Text] [Related]
33. A randomized prospective trial evaluating testosterone, haemoglobin kinetics and quality of life, during and after 12 months of androgen deprivation after prostatectomy: results from the Postoperative Adjuvant Androgen Deprivation trial.
Black PC; Basen-Engquist K; Wang X; Swartz RJ; Eddings T; Matin SF; Swanson D; Wood CG; Pisters LL; Babaian RJ; Troncoso P; Pettaway CA
BJU Int; 2007 Jul; 100(1):63-9. PubMed ID: 17552954
[TBL] [Abstract][Full Text] [Related]
34. Impact of salvage therapy for biochemical recurrence on health-related quality of life following radical prostatectomy.
Namiki S; Saito S; Tochigi T; Ioritani N; Terai A; Arai Y
Int J Urol; 2007 Mar; 14(3):186-91. PubMed ID: 17430252
[TBL] [Abstract][Full Text] [Related]
35. Retrospective comparison of external beam radiotherapy and radical prostatectomy in high-risk, clinically localized prostate cancer.
Arcangeli G; Strigari L; Arcangeli S; Petrongari MG; Saracino B; Gomellini S; Papalia R; Simone G; De Carli P; Gallucci M
Int J Radiat Oncol Biol Phys; 2009 Nov; 75(4):975-82. PubMed ID: 19395188
[TBL] [Abstract][Full Text] [Related]
36. Postoperative prostate-specific antigen velocity independently predicts for failure of salvage radiotherapy after prostatectomy.
King CR; Presti JC; Brooks JD; Gill H; Spiotto MT
Int J Radiat Oncol Biol Phys; 2008 Apr; 70(5):1472-7. PubMed ID: 17935902
[TBL] [Abstract][Full Text] [Related]
37. Health-related quality of life 2 years after treatment with radical prostatectomy, prostate brachytherapy, or external beam radiotherapy in patients with clinically localized prostate cancer.
Ferrer M; Suárez JF; Guedea F; Fernández P; Macías V; Mariño A; Hervas A; Herruzo I; Ortiz MJ; Villavicencio H; Craven-Bratle J; Garin O; Aguiló F;
Int J Radiat Oncol Biol Phys; 2008 Oct; 72(2):421-32. PubMed ID: 18325680
[TBL] [Abstract][Full Text] [Related]
38. Influence of body mass index on prostate-specific antigen failure after androgen suppression and radiation therapy for localized prostate cancer.
Efstathiou JA; Chen MH; Renshaw AA; Loffredo MJ; D'Amico AV
Cancer; 2007 Apr; 109(8):1493-8. PubMed ID: 17340594
[TBL] [Abstract][Full Text] [Related]
39. Targeted-cryosurgical ablation of the prostate with androgen deprivation therapy: quality of life in high-risk prostate cancer patients.
Kang SH; Kim JW; Bae JH; Park HS; Moon DG; Yoon DK; Cheon J; Kim JJ
Asian J Androl; 2006 Sep; 8(5):629-36. PubMed ID: 16847531
[TBL] [Abstract][Full Text] [Related]
40. Natural history of voiding function after radical retropubic prostatectomy.
Namiki S; Ishidoya S; Saito S; Satoh M; Tochigi T; Ioritani N; Yoshimura K; Terai A; Arai Y
Urology; 2006 Jul; 68(1):142-7. PubMed ID: 16777193
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
